



Entyvio in UAE

The MoHAP named-patient coordination pathway — indicative 2026

IMMUNOLOGY · ALPHA4BETA7 INTEGRIN

The clinical situation

Entyvio (vedolizumab) is an FDA-approved humanised monoclonal antibody to the gut-selective alpha4beta7 integrin indicated for moderately-to-severely active ulcerative colitis and Crohn disease. Manufactured by Takeda. Standard dosing is 300 mg IV at weeks 0, 2, and 6 then every 8 weeks (or SC 108 mg every 2 weeks after IV induction); refrigerated storage 2-8°C; IV at infusion centre, SC auto-injector patient-administered.

The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your treating gastroenterologist documents IBD diagnosis, disease activity, TB/HBV screening, and prior biologic history.
- 2 Treating centre confirmed.** A UAE tertiary gastroenterology / IBD centre in Abu Dhabi, Dubai, or Sharjah accepts the case.
- 3 MoHAP named-patient application.** Clinical rationale, patient reference, product details, and cold-chain plan are filed with the MoHAP NPP team; local emirate health authority coordination.
- 4 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner; temperature-monitored 2-8°C shipment.
- 5 Arrival & administration.** IV induction at the infusion centre; SC maintenance self-administered at home after nurse training; response reassessed at 14 weeks.

Indicative economics

Reference US cash-pay range: USD 6,000–7,500 per infusion. MoHAP documentation, cold-chain logistics, and concierge coordination are incremental. Full transparent quote at intake.

Indicative first-dose timing

7–14 days from a complete MoHAP application to first-dose delivery, once cohort intake opens. Indicative — not guaranteed.

Reserve Meds's role

Sourcing. US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** Regulatory package for your physician and MoHAP review. **Logistics.** Temperature-monitored cold-chain shipment coordination. **Concierge case lead.** Named point of contact for family and physician through the full process. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating gastroenterologist.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Entyvio × UAE first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemed.com/access-guides/entyvio-uae.html



SCAN TO JOIN

Reserve Meds · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.

reservemed.com · hello@reservemed.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team